These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 37586869)
1. Utility of circulating tumour DNA for prognosis and prediction of therapeutic effect in locally recurrent rectal cancer: study protocol for a multi-institutional, prospective observational study (JCOG1801A1, CAP-LR study). Hashimoto T; Tsukada Y; Ito M; Kanato K; Mizusawa J; Fukuda H; Tsukamoto S; Takashima A; Kanemitsu Y BMJ Open; 2023 Aug; 13(8):e073217. PubMed ID: 37586869 [TBL] [Abstract][Full Text] [Related]
2. BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer. Kasi PM; Sawyer S; Guilford J; Munro M; Ellers S; Wulff J; Hook N; Krinshpun S; Koyen Malashevich A; Malhotra M; Rodriguez A; Moshkevich S; Grothey A; Kopetz S; Billings P; Aleshin A BMJ Open; 2021 Sep; 11(9):e047831. PubMed ID: 34561256 [TBL] [Abstract][Full Text] [Related]
3. Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study. Schraa SJ; van Rooijen KL; van der Kruijssen DEW; Rubio Alarcón C; Phallen J; Sausen M; Simmons J; Coupé VMH; van Grevenstein WMU; Elias S; Verkooijen HM; Laclé MM; Bosch LJW; van den Broek D; Meijer GA; Velculescu VE; Fijneman RJA; Vink GR; Koopman M; BMC Cancer; 2020 Aug; 20(1):790. PubMed ID: 32819390 [TBL] [Abstract][Full Text] [Related]
4. Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. Tie J; Cohen JD; Wang Y; Li L; Christie M; Simons K; Elsaleh H; Kosmider S; Wong R; Yip D; Lee M; Tran B; Rangiah D; Burge M; Goldstein D; Singh M; Skinner I; Faragher I; Croxford M; Bampton C; Haydon A; Jones IT; S Karapetis C; Price T; Schaefer MJ; Ptak J; Dobbyn L; Silliman N; Kinde I; Tomasetti C; Papadopoulos N; Kinzler K; Volgestein B; Gibbs P Gut; 2019 Apr; 68(4):663-671. PubMed ID: 29420226 [TBL] [Abstract][Full Text] [Related]
5. A phase III randomized controlled trial comparing surgery plus adjuvant chemotherapy with preoperative chemoradiotherapy followed by surgery plus adjuvant chemotherapy for locally recurrent rectal cancer: Japan Clinical Oncology Group study JCOG1801 (RC-SURVIVE study). Kadota T; Tsukada Y; Ito M; Katayama H; Mizusawa J; Nakamura N; Ito Y; Bando H; Ando M; Onaya H; Fukuda H; Kanemitsu Y Jpn J Clin Oncol; 2020 Aug; 50(8):953-957. PubMed ID: 32409830 [TBL] [Abstract][Full Text] [Related]
6. BESPOKE IO protocol: a multicentre, prospective observational study evaluating the utility of ctDNA in guiding immunotherapy in patients with advanced solid tumours. Kasi PM; Chakrabarti S; Sawyer S; Krainock M; Poklepovic A; Ansstas G; Maninder M; Malhotra M; Ensor J; Gao L; Eroglu Z; Ellers S; Billings P; Rodriguez A; Aleshin A BMJ Open; 2022 May; 12(5):e060342. PubMed ID: 35636789 [TBL] [Abstract][Full Text] [Related]
7. Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study. Wang Y; Yang L; Bao H; Fan X; Xia F; Wan J; Shen L; Guan Y; Bao H; Wu X; Xu Y; Shao Y; Sun Y; Tong T; Li X; Xu Y; Cai S; Zhu J; Zhang Z PLoS Med; 2021 Aug; 18(8):e1003741. PubMed ID: 34464382 [TBL] [Abstract][Full Text] [Related]
8. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis. Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376 [TBL] [Abstract][Full Text] [Related]
9. Circulating tumor DNA detection after neoadjuvant treatment and surgery predicts recurrence in patients with early-stage and locally advanced rectal cancer. Hofste LSM; Geerlings MJ; von Rhein D; Rütten H; Westenberg AH; Weiss MM; Gilissen C; Hofste T; van der Post RS; Klarenbeek BR; de Wilt JHW; Ligtenberg MJL; Eur J Surg Oncol; 2023 Jul; 49(7):1283-1290. PubMed ID: 36740555 [TBL] [Abstract][Full Text] [Related]
10. ctDNA as a predictor of outcome after curative resection for locally advanced rectal cancer: systematic review and meta-analysis. Nassar A; Aly NE; Jin Z; Aly EH Colorectal Dis; 2024 Jul; 26(7):1346-1358. PubMed ID: 38802990 [TBL] [Abstract][Full Text] [Related]
11. Serial circulating tumour DNA analysis for locally advanced rectal cancer treated with preoperative therapy: prediction of pathological response and postoperative recurrence. Murahashi S; Akiyoshi T; Sano T; Fukunaga Y; Noda T; Ueno M; Zembutsu H Br J Cancer; 2020 Sep; 123(5):803-810. PubMed ID: 32565539 [TBL] [Abstract][Full Text] [Related]
12. Induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer: study protocol of a multicentre, open-label, parallel-arms, randomized controlled study (PelvEx II). PelvEx Collaborative BJS Open; 2021 May; 5(3):. PubMed ID: 34089596 [TBL] [Abstract][Full Text] [Related]
14. ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C). Slater S; Bryant A; Chen HC; Begum R; Rana I; Aresu M; Peckitt C; Zhitkov O; Lazaro-Alcausi R; Borja V; Powell R; Lowery D; Hubank M; Rich T; Anandappa G; Chau I; Starling N; Cunningham D BMC Cancer; 2023 Mar; 23(1):257. PubMed ID: 36941575 [TBL] [Abstract][Full Text] [Related]
15. A phase III randomized trial evaluating chemotherapy followed by pelvic reirradiation versus chemotherapy alone as preoperative treatment for locally recurrent rectal cancer - GRECCAR 15 trial protocol. Denost Q; Frison E; Salut C; Sitta R; Rullier A; Harji D; Maillou-Martinaud H; Rullier E; Smith D; Vendrely V; Colorectal Dis; 2021 Jul; 23(7):1909-1918. PubMed ID: 33843133 [TBL] [Abstract][Full Text] [Related]
16. Afatinib in combination with GEMOX chemotherapy as the adjuvant treatment in patients with ErbB pathway mutated, resectable gallbladder cancer: study protocol for a ctDNA-based, multicentre, open-label, randomised, controlled, phase II trial. Yang M; Zhao Y; Li Y; Cui X; Liu F; Wu W; Wang XA; Li M; Liu Y; Liu Y BMJ Open; 2023 Feb; 13(2):e061892. PubMed ID: 36854604 [TBL] [Abstract][Full Text] [Related]
17. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study. Tie J; Wang Y; Cohen J; Li L; Hong W; Christie M; Wong HL; Kosmider S; Wong R; Thomson B; Choi J; Fox A; Field K; Burge M; Shannon J; Kotasek D; Tebbutt NC; Karapetis C; Underhill C; Haydon A; Schaeffer J; Ptak J; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P PLoS Med; 2021 May; 18(5):e1003620. PubMed ID: 33939694 [TBL] [Abstract][Full Text] [Related]
18. Response prediction and risk stratification of patients with rectal cancer after neoadjuvant therapy through an analysis of circulating tumour DNA. Liu W; Li Y; Tang Y; Song Q; Wang J; Li N; Chen S; Shi J; Wang S; Li Y; Jiao Y; Zeng Y; Jin J EBioMedicine; 2022 Apr; 78():103945. PubMed ID: 35306340 [TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543 [TBL] [Abstract][Full Text] [Related]
20. Alternative clinical end points in rectal cancer--are we getting closer? Glynne-Jones R; Mawdsley S; Pearce T; Buyse M Ann Oncol; 2006 Aug; 17(8):1239-48. PubMed ID: 16873440 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]